Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (11329)	11/17/1997 5:54:00 PM
From: Flagrante Delictu	Read Replies (1) \| Respond to of 32384

squetch, The candidate compound selected will not have to be funded by LGND, IMO, as its funding through the NDA will be handled by Lilly. Why else do you think LGND has to give Lilly $20,000,000 in stock for the compound? It should be a compound with about $50,000,000.oo annual sales potential, which is too small to interest Lilly, but enough to interest us, inasmuch as we expect 80% gross margins on it prior to giving back 10% as royalties to Lilly. This also, IMO, may be a prelude to an opportunity for us to take over other cancer or women's health drugs that are below Lilly's screen. I do not know this will happen, but if we do a good job on the first one, why not? The other deal should be the announcement of the signing of the leptin deal that's been hanging fire since January. Bernie. P.S.I got all the allusions to the dill in Picadilly, including pickle , sourpuss, barrel. I also enjoyed them, as usual.